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Background. We assessed the efficacy of artemisinin-based combination therapies for treatment of uncomplicated falciparum 
malaria, with or without co-infecting Plasmodium spp., in Sumatera, Indonesia.
Methods. Febrile patients aged >6 months with uncomplicated P. falciparum were randomized to receive dihydroartemisinin-
piperaquine or artemether-lumefantrine, plus single-dose primaquine, and were followed for 42 days. Mixed Plasmodium infections 
were included; P. vivax infections received 14 days of primaquine. We retrospectively restricted the analysis to cases with polymerase 
chain reaction (PCR)–confirmed parasitemia. Recurrent parasitemia in follow-up was identified by species-specific nested PCR.
Results. Of the 3731 participants screened, 302 were enrolled and randomized. In the dihydroartemisinin-piperaquine 
arm, P. falciparum infections were confirmed by PCR in 59 participants, with mixed infections in 23 (39.0%). In the artemether-
lumefantrine arm, P. falciparum infections were confirmed by PCR in 55 participants, with mixed infections in 16 (29.0%). Both 
regimens were well tolerated, and symptoms improved rapidly in all treated participants. In the dihydroartemisinin-piperaquine 
arm, 1 P. falciparum recurrence (on day 7) and 6 P. malariae recurrences (1 had a mixed infection with P. falciparum) were identi-
fied during days 3–42 of follow-up. In the artemether-lumefantrine arm, 1 P. falciparum/P. malariae/P. vivax recurrence occurred on 
day 35. Submicroscopic persistence occurred during follow-up in 21 (37%) of 57 receiving dihydroartemisinin-piperaquine and 20 
(39%) of 51 receiving artemether-lumefantrine.
Conclusions. In Sumatera, both regimens effectively cleared initial parasitemia, but P. falciparum and P. malariae persisted in 
some individuals. Molecular species detection should be deployed in antimalarial efficacy trials in Indonesia.
Trial registration. NCT02325180.
Keywords.  artemisinin combination therapy; in vivo drug efficacy; multispecies malaria infections.
Artemisinin-based combination therapy (ACT), co-formulating 
a short-acting artemisinin with a long-acting partner drug, is 
currently recommended for uncomplicated falciparum ma-
laria. The widespread deployment of ACT, together with 
other control strategies, has reduced malaria morbidity and 
mortality, particularly in Africa [1]. ACT efficacy is threatened 
by Plasmodium falciparum with reduced susceptibility to both 
artemisinin and its partner drugs in the Greater Mekong subre-
gion (GMS) [2–5]. Declining ACT efficacy against P. falciparum 
to ACT in this region raises concern that multidrug resistance 
may emerge in other malaria-endemic countries [6, 7].
Indonesia lies to the south and east of mainland Southeast 
Asia, and nearly 70 million of its population are at risk of ma-
laria, including multispecies co-infections [8–10]. The ACT 
artesunate-amodiaquine, plus a single dose of primaquine 
to clear gametocytes, has been used for the treatment of un-
complicated falciparum malaria in Indonesia since 2004 [11]. 
Efficacy <90% was reported, and this combination was sub-
sequently replaced by dihydroartemisinin-piperaquine (DP), 
plus a single dose of primaquine [12, 13]. For non-falciparum 
malaria, the standard 3-day course of DP is also recommended 
in combination with 1–14  days of primaquine for certain 
infecting species [14]. Published estimates of ACT efficacy 
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against the non-falciparum parasite species in Indonesia exist 
only for P.  vivax, which commonly occurs either alone or in 
co-infections with P.  falciparum [8, 15], but no studies have 
adequately assessed the in vivo susceptibility of P. malariae or 
P. knowlesi, which co-circulate in Western Indonesia [8].
DP efficacy throughout Indonesia is reported to be excellent, 
and there are no reports of delayed clearance of P. falciparum, 
a sign of artemisinin resistance [13, 15–18]. However, a po-
tential threat remains of artemisinin-resistant parasites being 
introduced from the GMS [6], adjacent to West Indonesia, or 
from Niugini (PNG), with a land border to East Indonesia [7]. 
Thus, there is a need to evaluate P.  falciparum populations in 
Indonesia for susceptibility to current regimens in vivo. We 
aimed to compare the efficacy of DP, the first-line treatment for 
falciparum malaria, with artemether-lumefantrine (AL), also li-
censed in Indonesia, for treatment of uncomplicated falciparum 
malaria as single- and multispecies infections. The work was 
carried out in the North Sumatera province, which is a short sea 
crossing from Southern Thailand.
METHODS
Study Site and Participants
We conducted a prospective, open-label, randomized com-
parison of DP and AL for the treatment of uncomplicated 
falciparum malaria in the Batubara, Langkat, and South Nias 
regencies in the North Sumatera province, Western Indonesia 
(Supplementary Figure 1). Patients with uncomplicated P. falcip-
arum malaria (including mixed infections with non-falciparum 
species) were eligible if they were aged >6 months, had fever/
fever history (temperature ≥37.5°C) in the past 48 hours, and 
parasitemia >250 asexual parasites per µL, as determined by mi-
croscopic examination. Exclusion criteria were signs and symp-
toms of severe or complicated malaria, severe malnutrition, 
hemoglobin <7 g/dL, nonmalaria febrile illness, pregnancy or 
lactation, known hypersensitivity or allergy to study drugs, any 
antimalarial drug use in the previous 2 weeks, and any study 
drug use in the past 4 weeks.
The study was registered at ClinicalTrials.gov with the 
identifier NCT02325180 and approved by the Universitas 
Sumatera Utara (USU; August 2014; identifier 401/KOMET/
FK USU/2014) and London School of Hygiene and Tropical 
Medicine (LSHTM; October 2014; Ref: 8504)  research ethics 
committees. Consent forms were prepared in English and trans-
lated into Bahasa Indonesia. All adult participants and guard-
ians of those <18 years old provided written informed consent.
Procedures
DP (Duo-Cotecxin, Holley Pharmaceutical, Hangzhou, Zhejiang 
Province, China; 40 mg dihydroartemisinin, 320 mg piperaquine) 
was given at doses of 2.25 mg/kg/dose and 18 mg/kg/dose, ad-
ministered at enrollment, 24 hours, and 48 hours. AL (Coartem, 
Novartis Pharma, China; 40 mg artemether, 240 mg lumefantrine) 
was given according to weight, with 1 half-tablet for every 5 kg 
of body weight, at enrollment and hours 8, 24, 36, 48, and 60. 
DP was given on an empty stomach, and AL was given with 
biscuits or milk. Administration of all doses was supervised by 
study staff. Re-administration of a full dose or half-dose occurred 
if the patient vomited within 30 minutes or 30–60 minutes after 
treatment, respectively. As set out in Indonesian Government 
Treatment Guidelines, an additional single dose of primaquine 
at 0.75 mg/kg was given at enrollment for P. falciparum infection, 
and 14-day treatment with 0.25 mg/kg of primaquine per day was 
administered for all participants who were microscopy-positive 
for P. vivax at enrollment, commencing on day 42 [11].
Signs, symptoms, and adverse events were assessed and re-
corded before and during treatment and at all follow-up visits. 
Finger-prick blood samples provided blood films for micro-
scopic assessment and dried filter paper blood spots for post 
hoc molecular analysis. Parasitological assessments were made 
from Giemsa-stained thick and thin blood smears and were 
single-read by a study team microscopist.
Parasite DNA was isolated from filter paper, and polymerase 
chain reaction (PCR) amplification of 18S rRNA genes for mo-
lecular identification of Plasmodium spp., pfmdr1 amplification 
for P.  falciparum, and pksicavar amplification for P.  knowlesi 
was performed as previously described [8]. Parasite clearance 
at days 0, 1, 2, and 3 was measured using microscopy and by 
quantitative PCR (qPCR) for amplification of genus-specific 
pgmet normalized to the human β-tubulin gene humtubb, as 
previously described [19, 20]. Hemoglobin levels were assessed 
using HemoCue at enrollment and day 28.
Recurrent P. falciparum infections, identified by microscopy 
during routine follow-up (days 1, 2, 3, 7, 14, 21, 28, 35, 42), 
were treated with quinine (10 mg of salt/kg given 3 times a day 
for 7  days) and doxycycline (100  mg twice a day for 7  days), 
except for children aged <8  years and pregnant women, who 
were treated with quinine and clindamycin. Patients who devel-
oped a non-falciparum Plasmodium infection were re-treated 
according to the national guidelines [11]. Recurrent infections 
identified by microscopy were confirmed post hoc by species-
specific nested PCR amplification of 18S rRNA or merozoite an-
tigen genes [8, 21]. Subpatent P. falciparum recurrences on days 
28 and 42, or the latest available sample, were identified post 
hoc by PCR amplification of the pfmdr1 gene [22].
Outcomes
The primary end point defined in the study protocol was 
42-day adequate clinical and parasitological response (ACPR) 
following DP and AL treatment for P.  falciparum infection, 
as defined by the World Health Organization (WHO) [21]. 
Secondary and exploratory end points included qPCR parasite 
clearance over days 0 to 3; the proportion of patients with para-
sitemia at day 3 measured by microscopy and qPCR; efficacy of 
treatment against PCR-confirmed non-falciparum Plasmodium 
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spp.; and the proportion of patients with subpatent Plasmodium 
spp. recurrences at days 28 and 42.
Statistical Analysis
A sample size of 150 participants in each group would provide 
80% power to show the noninferiority of AL compared with DP 
at day 42, with an α of .05 and δ of 5%.
Data were double-entered and analyzed using Stata IC (ver-
sion 15; StataCorp, TX, USA). Those lost to follow-up or who 
withdrew from the study were censored as having treatment 
failure. Only those outcomes determined in the PCR-defined 
population are presented in this report. Odds ratios and 95% 
confidence intervals were estimated for testing associations; P 
values of ≤.05 were considered statistically significant.
RESULTS
A total of 3731 participants were screened from January to June 
2015 in the Regencies of in Batubara, Langkat, and South Nias 
(Supplementary Figure 1), as previously described [8]. Three 
hundred two individuals, comprising 263 P.  falciparum infec-
tions and 39 mixed P. falciparum/P. vivax, as identified by mi-
croscopy, were eligible for enrollment and randomly assigned 
to receive DP (n = 153) or AL (n = 149) (Figure 1). Both regi-
mens were well tolerated, and symptoms improved rapidly in all 
treated subjects. A single P. falciparum infection failed to clear 
by day 3 by microscopy in a patient receiving DP; post hoc PCR 
confirmed P. falciparum DNA (alone) at the day of enrollment. 
P.  malariae and P.  falciparum DNA were detected together at 
day 3 in this individual (Figure 1), and P.  falciparum gameto-
cytes were observed in the blood-film on days 1, 2, and 3, sug-
gesting a chronic infection.
We performed species-specific nested PCR retrospectively 
on DNA from enrollment samples of all 302 randomized in-
dividuals. Surprisingly, Plasmodium spp. DNA was success-
fully detected in only 195 individuals (Figure 1), indicating that 
lack of accuracy in microscopic diagnosis had resulted in the 
inappropriate recruitment of individuals without a detectable 
malaria infection. Further, P. falciparum parasite DNA was spe-
cifically amplified in just 117 randomized patients (38.8%), in 
40 of whom evidence was found of co-infecting Plasmodium 
spp. (Table 1). As a result of these findings, and excluding 5 in-
dividuals who did not complete 3 days of ACT treatment, we 
established a PCR-defined cohort (n = 190) and performed an 
exploratory efficacy assessment for each treatment group on a 
modified per-protocol basis, in which both enrollment and fol-
low-up parasite detection was performed by PCR (Figure  1). 
Comparison of baseline characteristics for the 114 evaluable 
P.  falciparum–infected individuals included in this analysis is 
given in Table 2.
Within the PCR-defined cohort, microscopically identi-
fied recurrent P.  falciparum infections during follow-up were 
3731 participants screened
Dihydroartemisinin-piperaquine
153
PCR negative 48
Recurrences by microscopy 17
PCR negative 10
P. falciparum 1 (day 7)
Recurrences by microscopy 5
PCR negative 4
P. falciparum/P. malariae/P. vivax 1 (day 35)
P. falciparum/P. malariae 1 (day 3a)
P. malariae 5 (days 7, 14, 14, 21, 42)
Incomplete ACT 3
PCR-defined cohort 102
P. falciparum positive 59
PCR-defined cohort 88
P. falciparum positive 55
PCR negative 59
Incomplete ACT 2
Artemether-lumefantrine
149
302 enrolled and randomized
Figure 1. Trial profile. PCR-defined cohorts were identified in each treatment arm as shown. Lower cells show PCR outcomes for 22 follow-up blood samples identified as 
recurrent infections by microscopy. aDenotes a single early treatment failure identified by microscopy and PCR-confirmed. Abbreviations: ACT, artemisinin-based combination 
therapy; PCR, polymerase chain reaction.
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reported for 22 patients (17 for DP, 5 for AL). Species-specific 
PCR on the follow-up samples failed to detect parasite DNA in 
10 and 4, respectively (Figure 1). Of the remainder, the majority 
harbored P.  malariae alone (at days 7, 14, 14, 21, and 42)  or 
mixed (day 3, 35), with only a single PCR-confirmed case of 
recurrent P. falciparum mono-infection (day 7). P. vivax DNA 
was detected in a single recurrence in the AL-treated group of 
the PCR-defined cohort at day 35, mixed with P. falciparum and 
P. malariae. Therefore, the specificity of microscopic identifica-
tion of recurrent parasitemia was poor in our study, as judged 
by post hoc PCR.
An exploratory analysis of drug efficacy was then performed 
on both treatment arms of our PCR-defined cohort. First, we 
investigated parasite clearance dynamics of PCR-confirmed 
P. falciparum infection. We generated qPCR data for all enrolled 
study subjects for which DNA samples were available at days 0, 
1, 2, and 3. Of the 114 confirmed P. falciparum patients, 60 were 
evaluated by qPCR at all 4 time points, 36 in the DP-treatment 
group and 24 in the AL group. Over 70% of patients in both 
groups cleared qPCR-detectable Plasmodium DNA within 24 
hours, and only 4 (11%) and 3 (12%) receiving DP and AL, re-
spectively, remained qPCR-positive at day 3 (Figure 2). Ninety 
percent or greater reduction in parasite density within 24 hours 
was achieved in 97% and 96% of patients treated with DP and 
AL, respectively. These data are consistent with continuing sus-
ceptibility to artemisinin in this P. falciparum population.
Table 2. Baseline Characteristics of Patients With PCR-Confirmed P. falciparum Infection
Characteristic PCR-Confirmed P. falciparum Infection
 Dihydroartemisinin-Piperaquine Group Artemether-Lumefantrine Group
No. of evaluable patients 59 55
Infecting species at enrollment,a No. (%)   
 P. falciparum 36 (61.0) 39 (70.9)
 P. falciparum and P. vivax 9 (15.3) 5 (9.1)
 P. falciparum and P. malariae 2 (3.4) 0 (0)
 P. falciparum and P. knowlesi 8 (13.6) 10 (18.2)
 P. falciparum, P. vivax, P. malariae 1 (1.7) 0 (0)
 P. falciparum, P. vivax, P. knowlesi 1 (1.7) 1 (1.8)
 P. falciparum, P. malariae, P. knowlesi 2 (3.4) 0 (0)
Median P. falciparum enrollment density (IQR), µL-1 320 (272–1160) 400 (272–1520)
Female sex, No. (%) 35 (59.3) 25 (45.5)
Age   
 Median (25%–75% range), y 11.8 (7–21) 22 (8–39)
 <5 y, No. (%) 10 (16.9) 5 (9.1)
 5–14 y, No. (%) 30 (50.9) 20 (36.4)
 ≥15 y, No. (%) 19 (32.2) 30 (54.6)
Temperature ≥37.5°C, No. (%) 9 (15.3) 8 (14.6)
Mean hemoglobin at enrollment (SD), g/dL 11.7 (1.9) 11.9 (1.7)
Mean hemoglobin at day 28 (SD), g/dL 11.8 (1.5) 11.7 (1.9)
No. of anemic patients (Hb <10.0 g/dL) (%) 8 (13.6) 4 (7.3)
Abbreviations: IQR, interquartile range; PCR, polymerase chain reaction. 
aIdentification and measurement by microscopy.
Table 1. Species-Specific PCR Detection Frequency of Parasites in All 302 Randomized Individuals, From Peripheral Blood Sampled at Day of Enrollment, 
by Amplification of 18S rRNA and sicavar Genes
Species 1
Additional Species
Total (%)None Pv Pk Pm Pm/Pk Pv/Pk Pv/Pm
Negative 107       107  (35.4)
Pf 77 14 18 2 3 2 1 117  (38.7)
Pv 28  16 4 3   51  (16.9)
Pk 19   2    21  (7.0)
Pm 6       6  (2.0)
Total 302
The table is arranged as a hierarchy based on prevalence in the data set, Pf>Pv>Pk>Pm, and does not necessarily reflect relative density in peripheral blood in mixed-species infections. 
Thus, all results are qualitative, so it cannot be assumed that, in a mixed infection, the species denoted by row is circulating at higher density than the species denoted by column in any 
particular individual.
Abbreviations: PCR, polymerase chain reaction; Pf, Plasmodium falciparum; Pk, Plasmodium knowlesi; Pm, Plasmodium malariae; Pv, Plasmodium vivax. 
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Second, with PCR-confirmed P. falciparum infections at en-
rollment, we identified parasite recurrence by nested PCR am-
plification of the pfmdr1 locus in all available 4- and 6-week 
follow-up samples. P. falciparum DNA was detected on days 28 
or 42 in 41% of evaluable patients in the DP group (n = 59), and 
35% in the AL group (n = 55; odds ratio, 0.833; 95% confidence 
interval, 0.365–1.89; P  =  .636) (Figure  3). Remarkably, all 24 
patients from Langkat harbored PCR-detectable P.  falciparum 
DNA at day 28 or day 42, whereas in Batubara and Nias the 
proportion was much lower, at 6/30 (20%) and 13/60 (22%), 
respectively.
Third, we explored ACT efficacy in patients harboring only 
non-falciparum malaria parasites, as measured by parasite 
clearance in the first 72 hours of treatment. Of 76 evaluable 
patients not harboring P. falciparum, 50 were PCR-positive for 
P. vivax at day 0, including 28 where this was the sole species 
(Table  1). Parasite clearance was measured in 30 of these in-
dividuals: All cleared qPCR-detectable parasitemia within 48 
hours, except for 1 individual treated with DP who cleared par-
asitemia within 72 hours and 1 individual treated with AL who 
harbored persistent day 3 parasitemia, estimated as 0.3% of the 
starting parasite density. Three of 17 AL-treated patients with 
P.  vivax (alone or mixed with P.  knowlesi and/or P.  malariae) 
were qPCR-positive at day 28 or day 42, equivalent to PCR-
detected treatment failure of 17.6%, and 1 of 31 DP-treated pa-
tients with P. vivax (alone or mixed) was qPCR-positive at day 
28, equivalent to a PCR-detected treatment failure of 3.2%. Of 
19 P. knowlesi mono-infections, 8 generated parasite clearance 
data, of which 1 was qPCR-positive on day 3; this AL-treated 
individual was again qPCR-positive on day 28. Four individ-
uals with P. malariae monoinfections at enrollment and 1 with 
both P. malariae and P. knowlesi were all qPCR-negative within 
24 hours of commencing treatment with AL (2) or DP (3). Our 
qPCR detection target is specific only to the genus level, and 
further identification of the species present was unsuccessful in 
post-treatment isolates, which were of a low density. However, 
later recurrence of P. malariae did occur in 7 individuals orig-
inally treated for PCR-confirmed P. falciparum. In conclusion, 
this off-protocol analysis demonstrates the potential for qPCR 
to provide estimates of post-treatment parasite clearance dy-
namics and to detect recrudescence in non-falciparum malaria.
DISCUSSION
We report the results of an open-label efficacy comparison of 
DP (n = 153) vs AL (n = 149) for the treatment of uncompli-
cated malaria in 3 Regencies of the North Sumatera province, 
where P. falciparum co-circulates with P. vivax, P. knowlesi, and 
P. malariae. This is the Indonesian region closest to the GMS, 
where P. falciparum with reduced susceptibility to artemisinin, 
associated with slow clearance of ACT-treated infections, first 
emerged. We sought information on the current efficacy of ACT 
in these settings. Poor diagnostic accuracy of clinic micros-
copy led to enrollment and randomization of many individuals 
who did not meet the enrollment criteria, thus hampering any 
meaningful analysis on an intention-to-treat basis. Similarly, 
post hoc species-specific PCR indicated that many microscopi-
cally identified recurrent infections in follow-up did not harbor 
Plasmodium spp. DNA and had been misclassified. We there-
fore deviated from our original study protocol and restricted 
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Figure 2. Parasite prevalence and relative parasite density as determined by 
qPCR at days 0, 1, 2, and 3. Prevalence of detectable Plasmodium DNA at each time 
point is shown as a percentage of tested individuals in each treatment group (ver-
tical bars). Parasite density relative to day 0 in the same individual is presented as 
the geometric mean of all DNA-positive samples at each time point (colored lines). 
Data are shown for all evaluable patients confirmed PCR-positive for P. falciparum 
at day 0 (n = 37 for DP [blue]; n = 25 for AL [orange]). Abbreviations: AL, artemether-
lumefantrine; DP, dihydroartemisinin-piperaquine; qPCR, quantitative polymerase 
chain reaction. 
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Figure 3. Survival rate of P.  falciparum recurrences detected by nested PCR of 
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P. falciparum infection at enrollment, with recurrent P. falciparum parasitemia after 
treatment with DP or AL detected by nested PCR of the pfmdr1 gene fragment 
encompassing codons 86 and 184. Abbreviations: AL, artemether-lumefantrine; DP, 
dihydroartemisinin-piperaquine.
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analysis to a PCR-defined per-protocol cohort comprising 
102 and 88 PCR-confirmed infections and assessed drug ef-
ficacy using both qualitative and quantitative DNA detection 
end points.
Clearance of PCR-confirmed P.  falciparum infections over 
the first 72 hours of treatment (measured by qPCR for 62 indi-
viduals) was rapid for both regimens, with only 11% and 12% 
remaining qPCR-positive at day 3. This suggests that P. falcip-
arum in Western Indonesia retains susceptibility to artemis-
inin, although the occurrence of 1 DP-treated individual with 
microscopy-positive (PCR-confirmed) early treatment failure 
on day 3 is of concern. Genotyping of this recrudescent day 3 
infection at resistance-associated loci has been reported else-
where [22]; it was found to carry a wild-type pfkelch13 gene, 
pfcrt 72–76 haplotype SVMNT, pfmdr1 86/184/1246 haplo-
type YYD, and multiple copies of the pfmdr1 gene. The pfcrt 
genotype is known to be an important modulator of parasite 
response to a variety of current antimalarials, including arte-
misinin, lumefantrine, and piperaquine [23, 24], but no studies 
have systematically examined the impact of the SVMNT haplo-
type on P. falciparum susceptibility to these drugs. We recently 
identified isolates from the China-Myanmar border region with 
the SVMNT haplotype of pfcrt also harboring pfk13 propeller-
domain mutations [25].
Two elements of our study provide reasons to be cautious 
regarding any firm conclusions about P.  falciparum artemis-
inin susceptibility. First, our study was planned as a treat-
ment trial for falciparum malaria patients, with and without 
other co-infecting species, expected to be P.  vivax (https://
clinicaltrials.gov: NCT02325180), but randomization between 
the 2 treatment arms was seriously compromised because of 
the large number of uninfected enrollees (Figure  1, Table  1). 
Randomization may also have potentially been compromised 
by the ad hoc screening procedure, in which participants were 
identified by different means across the 3 sites [8]. For this 
reason, we do not present any comparative statistical analysis 
between the drug arms, but present descriptive statistics only. 
Second, as demonstrated by our community-wide study, car-
ried out simultaneously during recruitment, there is a complex 
mix of 4 Plasmodium species circulating in our study areas [8]. 
The use of DNA amplification methods to confirm the species 
present and to verify cases of putative treatment failure, was 
therefore important in determining the real (per-protocol) de-
nominator of treatment failure in each treatment group, but is 
not a recognized approach to therapeutic efficacy studies.
A minority of microscopically detected parasite recurrences 
were confirmed to be PCR-positive for Plasmodium spp., and 
surprisingly the majority of these were due to P. malariae, de-
spite P. vivax (68 individuals) and P. knowlesi (65 individuals) 
being much more prevalent at enrollment (Table  1). Our re-
sults therefore suggest that artemisinin is effective at rapidly 
clearing the majority of P. vivax and P. knowlesi infections and 
that P. malariae can rebound to microscopy- or PCR-detectable 
levels 2–6 weeks after ACT treatment. This is consistent with 
reports of P. malariae recurrence after ACT treatment in Ghana 
and Uganda [26, 27], with suggestions that the 72-hour intra-
erythrocytic cycle of P.  malariae provides an opportunity for 
this species to survive 3-day artemisinin exposure [28, 29]. This 
supports the argument that extended artemisinin regimens may 
be required for radical cure [30, 31], but these findings must be 
interpreted cautiously, given the problems with parasite identi-
fication at screening and enrollment.
Estimates of drug efficacy against PCR-confirmed P.  falcip-
arum infection were determined in each group at days 28 and 
42. Here we found evidence of submicroscopic parasite persist-
ence at day 28 and/or day 42 in 41% and 36% of the DP and 
AL groups, respectively (Figure 3). We conclude that, although 
both regimens seem effective at clearing initial parasitemia by 
qPCR, P. falciparum recurrence was a common occurrence with 
both regimens. Unfortunately, these presumably subpatent in-
fections were not of sufficient parasite density to permit strain 
genotyping, but it is safe to say that neither 3-day ACT regimen 
provided protection against persistent submicroscopic P. falcip-
arum for treated individuals at 4–6 weeks. As previously argued, 
longer sequential ACT treatment regimens over 6  days may 
provide both effective initial parasite clearance and prevention 
of P. falciparum recurrence [30], a strategy also likely to prove 
beneficial against P. malariae in North Sumatera [31].
Our results present a confusing picture of apparent good ar-
temisinin efficacy, evidenced by satisfactory parasite clearance 
of all infecting Plasmodium species by day 3, overlaid by com-
plex patterns of multispecies parasite recurrence manifested 
as PCR-detectable P.  falciparum and microscopy-detectable 
P. malariae. Parasite DNA detection is not a recognized measure 
of antimalarial treatment outcome, and only microscopically 
detected parasitological treatment failure is recognized by cur-
rent WHO protocols. This remains the appropriate current 
standard, as there are uncertainties as to the exact meaning of 
persistent parasite DNA in the treated individual. For example, 
in the case of P. falciparum, gametocyte emergence occurs late 
in infection and can provide a DNA biomarker in a treated in-
dividual despite effective clearance of all replicating asexual 
parasites [20]. It can also be argued that drug-killed parasites 
bequeath sufficient circulating DNA in the host that a positive 
PCR result does not necessarily mean viable, replicating para-
sites are still present. However, the lack of evidence that P. vivax 
DNA persisted in our treated individuals and work in both ro-
dent malaria [32] and ACT-treated human infections where 
even hyperparasitemic patients rapidly become PCR-negative 
[19] strongly suggest this is not the case. Nevertheless, the re-
sults presented here suggest that work toward a new protocol 
for therapeutic efficacy studies for antimalarial drugs, in which 
molecular detection methods are intrinsic to enrollment as well 
as to outcomes, is needed.
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The complexity of malaria in our study areas may be the re-
sult of human communities being isolated with poor access to 
diagnosis and treatment for malaria, as well as a tendency for 
low-density, multispecies chronic infections to develop among 
individuals exposed to regular mosquito challenge in these 
settings [8, 26]. Such established infections elicit immune re-
sponses from the host and can enter a steady state maintained 
by antigenic variation, and therefore may be more difficult to 
treat than acute infections [27]. This provides an additional ra-
tionale for the evaluation of extended ACT regimes as a means 
to reduce persistent parasitemia in treated individuals [30]. The 
complexity of malaria infections in Sumatera is a challenge for 
point-of-care diagnosis as well as for patient recruitment for 
antimalarial efficacy trials, as recently noted in neighboring 
Aceh Province [10], suggesting that further diagnostic and sur-
veillance capacities are needed in the region [33].
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